Novavax | NVAX - Net Income


Novavax reported $17.53M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
Adma Biologics USD 45.33M 4.05M Mar/2026
Agenus USD -10.63M 74.49M Dec/2025
AstraZeneca USD 3.08B 754M Mar/2026
BioCryst Pharmaceuticals USD 245.84M 232.95M Dec/2025
Cassava Sciences USD -10.33M 2.21M Mar/2026
Geron USD -3.64M 27.5M Mar/2026
GlaxoSmithKline GBP 1.74B 1.1B Mar/2026
MannKind USD -15.95M 23.93M Dec/2025
Merck USD -4.24B 7.2B Mar/2026
Minerva Neurosciences USD 1.44M 21.07M Dec/2024
Moderna USD -1.34B 517M Mar/2026
Novartis USD 3.16B 747M Mar/2026
Novavax USD 17.53M 219.91M Dec/2025
Pfizer USD 2.69B 4.34B Mar/2026
Sanofi EUR 1.61B 2.42B Mar/2026
Sarepta Therapeutics USD 330.96M 743.18M Mar/2026
TG Therapeutics USD 19.78M 3.26M Mar/2026